• Fred Rottnek, Sheryl Lyss, John Hartman, Geoffrey Panjeton, and Amanda Hilmer.
• From the Family Medicine and Addiction Medicine, SSM Health SLUCare and Saint Louis University School of Medicine (FR); Family Medicine and Addiction Medicine, SSM Health SLUCare and Saint Louis University School of Medicine (SL); Saint Louis University School of Medicine (JH); Anesthesiology and Critical Care, SSM Health SLUCare and Saint Louis University School of Medicine (GP); Family Medicine and Addiction Medicine, SSM Health SLUCare and Saint Louis University School of Medicine (AH). Fred.Rottnek@health.slu.edu).
• J Am Board Fam Med. 2024 Jul 1; 37 (4): 784789784-789.

AbstractFamily physicians are fielding questions about cannabis --particularly for the use of cannabis for treatment of pain. Like about every substance ingested to treat medical conditions, cannabis has risks and benefits. But regarding evidence-based practice and practice-based recommendations for patients about cannabis use, the cart is in front of the horse. Cannabis use is still illegal at a federal level and a Schedule 1 drug, but most states have challenged federal law by decriminalizing or legalizing cannabis for a variety of uses. Research is difficult due to this federal status as a Schedule 1 drug since federal funding is not readily available to support research. As a result, physicians have little to no guidance about the clinical usefulness of the product. This article explores what we know and what we are learning about cannabis, and the authors provide clinical guidance for patient care based on this evidence.© Copyright by the American Board of Family Medicine.

18 keywords...

hide…